ABOUT   |   AIMS and SCOPE   |   AUTHOR INSTRUCTIONS   |   EDITORIAL BOARD   |   ARCHIVE   |   CURRENT ISSUE   |   SUBMIT MANUSCRIPT ONLINE  |

This Article

Copyright © 2012 | AIZEON publishers | All rights reserved

 Open Access
 Abstract Free
 Full Text PDF Free

 

Services

Articles by corresponding author in PubMed

Articles by corresponding author in Google Scholar

 

 

 

aizeon

 



 

International Journal of Computational Bioinformatics and In Silico Modeling
2013: Volume-2 Issue-1
ISSN: 2320-0634

>>Back to Issues

ABSTRACT   REFERENCES  
International Journal of Computational Bioinformatics and In Silico Modeling 2(1) 2013: 68-71

In Silico molecular docking analysis to identify PI3K inhibitors as possible NSCLC agents


Awantika Shrivastava1*, K Durga Prasad1 and Archana Giri2

1Natco Research Centre, B-13, Industrial estate, Sanath Nagar, Hyderabad, India.
2Department of Biotechnology, JNTU, Kukatpally, Hyderabad, India.

* To whom correspondence should be addressed. Email: awantika31@rediffmail.com

ABSTRACT

Phosphatidylinositol 3-kinase is a very promising anti cancer drug target which is being actively investigated for treatment of various cancers such as RCC, prostrate, NSCLC and solid tumors. In this article, we have made an attempt to study the role of PI3K pathway inhibitors in the treatment of lung cancer through Insilco Molecular Docking studies. It was indicated from our study that the docking protocol could reliably predict how PI3K inhibitors act in NSCLC. The docking study carried out with 1M17 revealed that all six PI3K inhibitors have potential to work for NSCLC, but GDC-0941 (-7.03 kcal/mol) and GSK 2126458 (-8.30 kcal/mol) fits better than the rest.

Copyright © 2013 | AIZEON publishers | All rights reserved

..........................................................................................................................................................................................................

Citation: Awantika Shrivastava, K Durga Prasad and Archana Giri (2013). In Silico molecular docking analysis to identify PI3K inhibitors as possible NSCLC agents. Int J Comput Bioinfo In Silico Model 2(1): 68-71

..........................................................................................................................................................................................................